Kenji Tamura1, Chiyo K Imamura2, Toshimi Takano3, Shigehira Saji4, Takeharu Yamanaka5, Kan Yonemori1, Masato Takahashi6, Junji Tsurutani7,8, Reiki Nishimura9, Kazuhiko Sato10, Akira Kitani11, Naoto T Ueno12, Taisei Mushiroda13, Michiaki Kubo13, Yasuhiro Fujiwara1, Yusuke Tanigawara2. 1. National Cancer Center Hospital, Tokyo, Japan. 2. Keio University School of Medicine, Tokyo, Japan. 3. Toranomon Hospital, Tokyo, Japan. 4. Fukushima Medical University, Fukushima, Japan. 5. Yokohama City University School of Medicine, Yokohama, Japan. 6. National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan. 7. Kindai University, Osaka, Japan. 8. Showa University, Tokyo, Japan. 9. Kumamoto Shinto General Hospital, Kumamoto, Japan. 10. Tokyo-West Tokushukai Hospital, Tokyo, Japan. 11. Seirei Sakura Citizen Hospital, Chiba, Japan. 12. The University of Texas MD Anderson Cancer Center, Houston, TX. 13. RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Abstract
PURPOSE: In patients taking tamoxifen, the CYP2D6 genotype causes different exposure of active metabolite endoxifen. The objective of this randomized, open-label, multicenter, phase II study was to prospectively evaluate whether CYP2D6 genotype-guided tamoxifen dosing in patients with hormone receptor-positive metastatic breast cancer could have an impact on the clinical outcome. METHODS:Patients who needed first-line tamoxifen therapy were enrolled. Based on individual CYP2D6 genotype, patients heterozygous (wild type [wt]/variant [V]) or homozygous (V/V) for variant alleles of decreased or no function were randomly assigned to receive tamoxifen at an increased dose (ID arm; 40 mg daily) or regular dose (RD arm; 20 mg daily), and patients homozygous for wild-type alleles (wt/wt) received tamoxifen at 20 mg daily. The primary endpoint was the progression-free survival (PFS) rate at 6 months. The secondary endpoints included PFS and correlation of Z-endoxifen concentration with clinical outcomes. RESULTS:Between December 2012 and July 2016, 186 patients were enrolled in Japan. Of 184 evaluable patients, 136 carried wt/V or V/V (ID arm, 70; RD arm, 66), and 48 carried wt/wt. PFS rates at 6 months were not significantly different between the ID and RD arms (67.6% v 66.7%). The serum trough concentrations of Z-endoxifen in the ID arm were significantly higher than those in the RD arm (median, 89.2 nM v 51.1 nM; P < .0001) and were also higher compared with wt/wt patients (72.0 nM; P = .045). No significant difference in Z-endoxifen concentrations was observed between patients with disease progression and those who were progression free at 6 months (P = .43). CONCLUSION: In patients with CYP2D6-variant alleles, increasing tamoxifen dosing did not achieve a higher PFS rate at 6 months. The CYP2D6 genotype solely cannot explain individual variability in the efficacy of tamoxifen.
RCT Entities:
PURPOSE: In patients taking tamoxifen, the CYP2D6 genotype causes different exposure of active metabolite endoxifen. The objective of this randomized, open-label, multicenter, phase II study was to prospectively evaluate whether CYP2D6 genotype-guided tamoxifen dosing in patients with hormone receptor-positive metastatic breast cancer could have an impact on the clinical outcome. METHODS:Patients who needed first-line tamoxifen therapy were enrolled. Based on individual CYP2D6 genotype, patients heterozygous (wild type [wt]/variant [V]) or homozygous (V/V) for variant alleles of decreased or no function were randomly assigned to receive tamoxifen at an increased dose (ID arm; 40 mg daily) or regular dose (RD arm; 20 mg daily), and patients homozygous for wild-type alleles (wt/wt) received tamoxifen at 20 mg daily. The primary endpoint was the progression-free survival (PFS) rate at 6 months. The secondary endpoints included PFS and correlation of Z-endoxifen concentration with clinical outcomes. RESULTS: Between December 2012 and July 2016, 186 patients were enrolled in Japan. Of 184 evaluable patients, 136 carried wt/V or V/V (ID arm, 70; RD arm, 66), and 48 carried wt/wt. PFS rates at 6 months were not significantly different between the ID and RD arms (67.6% v 66.7%). The serum trough concentrations of Z-endoxifen in the ID arm were significantly higher than those in the RD arm (median, 89.2 nM v 51.1 nM; P < .0001) and were also higher compared with wt/wt patients (72.0 nM; P = .045). No significant difference in Z-endoxifen concentrations was observed between patients with disease progression and those who were progression free at 6 months (P = .43). CONCLUSION: In patients with CYP2D6-variant alleles, increasing tamoxifen dosing did not achieve a higher PFS rate at 6 months. The CYP2D6 genotype solely cannot explain individual variability in the efficacy of tamoxifen.
Authors: S Garte; L Gaspari; A K Alexandrie; C Ambrosone; H Autrup; J L Autrup; H Baranova; L Bathum; S Benhamou; P Boffetta; C Bouchardy; K Breskvar; J Brockmoller; I Cascorbi; M L Clapper; C Coutelle; A Daly; M Dell'Omo; V Dolzan; C M Dresler; A Fryer; A Haugen; D W Hein; A Hildesheim; A Hirvonen; L L Hsieh; M Ingelman-Sundberg; I Kalina; D Kang; M Kihara; C Kiyohara; P Kremers; P Lazarus; L Le Marchand; M C Lechner; E M van Lieshout; S London; J J Manni; C M Maugard; S Morita; V Nazar-Stewart; K Noda; Y Oda; F F Parl; R Pastorelli; I Persson; W H Peters; A Rannug; T Rebbeck; A Risch; L Roelandt; M Romkes; D Ryberg; J Salagovic; B Schoket; J Seidegard; P G Shields; E Sim; D Sinnet; R C Strange; I Stücker; H Sugimura; J To-Figueras; P Vineis; M C Yu; E Taioli Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-12 Impact factor: 4.254
Authors: Anabel Sanchez-Spitman; Vincent Dezentjé; Jesse Swen; Dirk Jan A R Moes; Stefan Böhringer; Erdogan Batman; Edith van Druten; Carolien Smorenburg; Aart van Bochove; Anneke Zeillemaker; Lynn Jongen; Maartje Los; Patrick Neven; Hans Gelderblom; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2019-01-24 Impact factor: 44.544
Authors: William J Irvin; Christine M Walko; Karen E Weck; Joseph G Ibrahim; Wing K Chiu; E Claire Dees; Susan G Moore; Oludamilola A Olajide; Mark L Graham; Sean T Canale; Rachel E Raab; Steven W Corso; Jeffrey M Peppercorn; Steven M Anderson; Kenneth J Friedman; Evan T Ogburn; Zeruesenay Desta; David A Flockhart; Howard L McLeod; James P Evans; Lisa A Carey Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: Michael D Johnson; Hong Zuo; Kyung-Hoon Lee; Joseph P Trebley; James Michael Rae; Ross V Weatherman; Zeruesanay Desta; David A Flockhart; Todd C Skaar Journal: Breast Cancer Res Treat Date: 2004-05 Impact factor: 4.872
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Werner Schroth; Matthew P Goetz; Ute Hamann; Peter A Fasching; Marcus Schmidt; Stefan Winter; Peter Fritz; Wolfgang Simon; Vera J Suman; Matthew M Ames; Stephanie L Safgren; Mary J Kuffel; Hans Ulrich Ulmer; Julia Boländer; Reiner Strick; Matthias W Beckmann; Heinz Koelbl; Richard M Weinshilboum; James N Ingle; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch Journal: JAMA Date: 2009-10-07 Impact factor: 56.272
Authors: James M Rae; Suzy Drury; Daniel F Hayes; Vered Stearns; Jacklyn N Thibert; Ben P Haynes; Janine Salter; Ivana Sestak; Jack Cuzick; Mitch Dowsett Journal: J Natl Cancer Inst Date: 2012-03-06 Impact factor: 13.506
Authors: P Saladores; T Mürdter; D Eccles; B Chowbay; N K Zgheib; S Winter; B Ganchev; B Eccles; S Gerty; A Tfayli; J S L Lim; Y S Yap; R C H Ng; N S Wong; R Dent; M Z Habbal; E Schaeffeler; M Eichelbaum; W Schroth; M Schwab; H Brauch Journal: Pharmacogenomics J Date: 2014-08-05 Impact factor: 3.550
Authors: C Louwrens Braal; Agnes Jager; Esther Oomen-de Hoop; Justin D Westenberg; Koen M W T Lommen; Peter de Bruijn; Mijntje B Vastbinder; Quirine C van Rossum-Schornagel; Martine F Thijs-Visser; Robbert J van Alphen; Liesbeth E M Struik; Hanneke J M Zuetenhorst; Ron H J Mathijssen; Stijn L W Koolen Journal: Clin Pharmacokinet Date: 2021-11-17 Impact factor: 6.447